ReviewNetherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation2016
Pulmonary hypertension complicating pulmonary sarcoidosis.
Review in Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- The Neutrophil-to-lymphocyte ratio as a diagnostic and prognostic biomarker in pulmonary hypertension: A systematic review.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Emerging Mechanistic Insights and Therapeutic Strategies for Pulmonary Arterial Hypertension: A Focus on Right Ventricular Dysfunction and Novel Treatment Pathways.Biomedicines · 2025Review
- Sarcoidosis-Associated Pulmonary Hypertension.Journal of clinical medicine · 2024Review
- Pulmonary Hypertension Associated Genetic Variants in Sarcoidosis Associated Pulmonary Hypertension.Diagnostics (Basel, Switzerland) · 2022Article
- Healthcare resource utilization and quality of life in patients with sarcoidosis-associated pulmonary hypertension.Pulmonary circulation · 2022Article
- WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT™) questionnaire in patients with sarcoidosis-associated pulmonary hypertension (SAPH): a qualitative interview study.BMC pulmonary medicine · 2021Article
- Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes.Diagnostics (Basel, Switzerland) · 2021Review
- The Importance of Multimodality Imaging in the Diagnosis and Management of Patients with Infiltrative Cardiomyopathies: An Update.Diagnostics (Basel, Switzerland) · 2021Review
- Predicting pulmonary hypertension in sarcoidosis; value of PH probability on echocardiography.The international journal of cardiovascular imaging · 2020Article
- Management of Sarcoidosis-associated Pulmonary Hypertension.Clinical medicine & research · 2020Article
- Author Response: Pulmonary Vasodilators in Sarcoidosis-associated Pulmonary Hypertension.Clinical medicine & research · 2020Article
- Echocardiography in Sarcoidosis.Current cardiology reports · 2018Review
- Predictive value of pulmonary function testing in the evaluation of pulmonary hypertension in sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2018Article
- Pulmonary hypertension: the importance of a multidisciplinary approach.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2016Article
- Mimickers of chronic thromboembolic pulmonary hypertension on imaging tests: a review.Pulmonary circulationArticle
- A case of sarcoidosis-associated pulmonary hypertension masquerading as chronic thromboembolic pulmonary hypertension.Pulmonary circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary hypertension (PH) is a severe complication of sarcoidosis, with an unknown prevalence. The aetiology is multifactorial, and the exact mechanism of PH in the individual patient is often difficult to establish. The diagnostic work-up and treatment of PH in sarcoidosis is complex, and should therefore be determined by a multidisciplinary expert team in a specialised centre. It is still a major challenge to identify sarcoidosis patients at risk for developing PH. There is no validated algorithm when to refer a patient suspected for PH, and PH analysis itself is difficult. Until present, there is no established therapy for PH in sarcoidosis. Besides optimal treatment for sarcoidosis, case series evaluating new therapeutic options involving PH-targeted therapy are arising for a subgroup of patients. This review summarises the current knowledge regarding the aetiology, diagnosis and possible treatment options for PH in sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.